Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Clerkship | 4 | 2015 | 116 | 0.710 |
Why?
|
| Radiation Oncology | 4 | 2015 | 119 | 0.690 |
Why?
|
| Program Evaluation | 4 | 2018 | 297 | 0.570 |
Why?
|
| Clinical Competence | 4 | 2018 | 751 | 0.510 |
Why?
|
| Vitreoscilla | 2 | 2013 | 2 | 0.470 |
Why?
|
| Nutritionists | 1 | 2013 | 3 | 0.460 |
Why?
|
| Dietetics | 1 | 2013 | 3 | 0.460 |
Why?
|
| Truncated Hemoglobins | 1 | 2013 | 1 | 0.460 |
Why?
|
| Professional Role | 1 | 2013 | 41 | 0.450 |
Why?
|
| Tyrosine | 1 | 2013 | 133 | 0.440 |
Why?
|
| Carbon Monoxide | 1 | 2013 | 90 | 0.440 |
Why?
|
| Needs Assessment | 2 | 2014 | 154 | 0.420 |
Why?
|
| Research | 1 | 2013 | 253 | 0.410 |
Why?
|
| Oxygen | 1 | 2013 | 726 | 0.310 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 864 | 0.290 |
Why?
|
| Students, Medical | 4 | 2015 | 384 | 0.270 |
Why?
|
| Plant Proteins | 3 | 2008 | 132 | 0.230 |
Why?
|
| Allergens | 3 | 2008 | 179 | 0.220 |
Why?
|
| Career Choice | 2 | 2014 | 139 | 0.210 |
Why?
|
| Methylmethacrylate | 1 | 2002 | 6 | 0.210 |
Why?
|
| Spinal Cord Compression | 1 | 2002 | 27 | 0.210 |
Why?
|
| Spinal Neoplasms | 1 | 2002 | 50 | 0.210 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 49 | 0.210 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 87 | 0.200 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 121 | 0.200 |
Why?
|
| Curriculum | 3 | 2015 | 539 | 0.200 |
Why?
|
| Spinal Fusion | 1 | 2002 | 85 | 0.200 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 148 | 0.190 |
Why?
|
| Crystallography, X-Ray | 6 | 2013 | 485 | 0.190 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
| Escherichia coli | 4 | 2013 | 597 | 0.160 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2007 | 6 | 0.160 |
Why?
|
| Crystallization | 8 | 2008 | 206 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 736 | 0.150 |
Why?
|
| Recombinant Proteins | 4 | 2013 | 1014 | 0.140 |
Why?
|
| Protein Structure, Secondary | 3 | 2013 | 330 | 0.140 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2015 | 48 | 0.130 |
Why?
|
| Data Collection | 2 | 2014 | 372 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2018 | 359 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 369 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
| Queensland | 1 | 2013 | 5 | 0.120 |
Why?
|
| Carcinoma, Large Cell | 1 | 2013 | 39 | 0.110 |
Why?
|
| Achievement | 1 | 2013 | 29 | 0.110 |
Why?
|
| Phenylalanine | 1 | 2013 | 37 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 52 | 0.110 |
Why?
|
| Proline | 1 | 2013 | 57 | 0.110 |
Why?
|
| Alanine | 1 | 2013 | 85 | 0.110 |
Why?
|
| Models, Molecular | 3 | 2013 | 1286 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 279 | 0.110 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 388 | 0.110 |
Why?
|
| Globulins | 2 | 2008 | 2 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 168 | 0.100 |
Why?
|
| Ligands | 1 | 2013 | 433 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 397 | 0.100 |
Why?
|
| Seeds | 2 | 2008 | 49 | 0.100 |
Why?
|
| Antigens, Plant | 2 | 2007 | 14 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 318 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 301 | 0.100 |
Why?
|
| Mortality | 1 | 2011 | 149 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 534 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 999 | 0.090 |
Why?
|
| Binding Sites | 1 | 2013 | 1098 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2011 | 255 | 0.090 |
Why?
|
| Corylus | 1 | 2008 | 1 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2018 | 1004 | 0.080 |
Why?
|
| Ginkgo biloba | 1 | 2008 | 5 | 0.080 |
Why?
|
| Pinus | 1 | 2007 | 3 | 0.080 |
Why?
|
| Bertholletia | 1 | 2007 | 1 | 0.080 |
Why?
|
| Survival Rate | 3 | 2013 | 1863 | 0.080 |
Why?
|
| Arachis | 1 | 2007 | 10 | 0.080 |
Why?
|
| Humans | 15 | 2018 | 86643 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2007 | 29 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2007 | 119 | 0.070 |
Why?
|
| X-Ray Diffraction | 4 | 2008 | 124 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2007 | 233 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1076 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 1169 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 763 | 0.070 |
Why?
|
| Thioredoxins | 1 | 2005 | 13 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 3640 | 0.060 |
Why?
|
| Spliceosomes | 1 | 2005 | 45 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1075 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2007 | 471 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 2898 | 0.060 |
Why?
|
| Male | 6 | 2014 | 40965 | 0.060 |
Why?
|
| Protein Engineering | 1 | 2003 | 140 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 1313 | 0.050 |
Why?
|
| Female | 5 | 2014 | 44532 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 2262 | 0.050 |
Why?
|
| Cause of Death | 1 | 2002 | 277 | 0.050 |
Why?
|
| Adult | 5 | 2018 | 25648 | 0.050 |
Why?
|
| Aged | 4 | 2018 | 18415 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 1686 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 268 | 0.040 |
Why?
|
| Seed Storage Proteins | 2 | 2007 | 2 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2007 | 99 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 6509 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 3030 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2005 | 1565 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1721 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2008 | 244 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 2767 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2015 | 72 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 107 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2015 | 273 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 33 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 646 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 29 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 115 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 133 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 124 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 300 | 0.030 |
Why?
|
| Middle Aged | 3 | 2013 | 25028 | 0.030 |
Why?
|
| United States | 2 | 2018 | 6672 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2007 | 8489 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 176 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1219 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 638 | 0.030 |
Why?
|
| Base Sequence | 2 | 2007 | 2330 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2601 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2207 | 0.030 |
Why?
|
| Internet | 1 | 2014 | 312 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 172 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 190 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 589 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 5976 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.020 |
Why?
|
| Insulin | 1 | 2015 | 1160 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2426 | 0.020 |
Why?
|
| Soybean Proteins | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Salts | 1 | 2008 | 16 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 93 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3990 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3092 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1939 | 0.020 |
Why?
|
| Food Hypersensitivity | 1 | 2008 | 63 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 2007 | 103 | 0.020 |
Why?
|
| Urination | 1 | 2007 | 37 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 177 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2008 | 154 | 0.020 |
Why?
|
| Child | 1 | 2018 | 6927 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 351 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 150 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 144 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1373 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 3679 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2005 | 157 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 1204 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2003 | 5 | 0.020 |
Why?
|
| Cytochromes b | 1 | 2003 | 9 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2062 | 0.010 |
Why?
|
| Color | 1 | 2003 | 81 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2003 | 122 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 179 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 927 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 5210 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 439 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11352 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 696 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 7993 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 26582 | 0.010 |
Why?
|